• Fresh Hope of a Functional Cure for HIV

    Bio-IT World | The longstanding reality for most individuals infected with human immunodeficiency virus (HIV) is a lifetime of taking antiretroviral therapy (ART). But the creation of an HIV-like virus particle that both reduces viral reservoirs and boosts the immune system could make it possible for at least half of all patients to achieve long-term control of the virus after a brief stint of treatment.

    Oct 2, 2024

  • New Alzheimer’s Approach Suggested by Data Mining

    Bio-IT World | In a paper published last month in Brain, researchers explored data from 24 past Alzheimer’s Disease trials and posited a new theory for why the most recent drugs have shown some success against the disease, and senior author Alberto Espay issued an open data challenge for pharma companies working in the space.

    Oct 1, 2024

  • Follow the Money: T Cell Engineering, Kidney Transplants, Intravascular Imaging Technology, More

    Bio-IT World | ArsenalBio plans to advance their lead programs through development invests in candidates for solid tumor cancers based on its proprietary T cell engineering technology; eGenesis moves to a first-in-human study for kidney transplant; SpectraWAVE will advance commercial expansion and product additions to their 510k-cleared HyperVue Imaging System; and more.

    Sep 26, 2024

  • Illumina Reacts to GRAIL Acquisition Ruling, AstraZeneca, Moffitt Cancer Center Partnership, 10x Genomics Platforms Mentioned, More

    Bio-IT World | Illumina welcomed the European Court of Justice's judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL; Moffitt Cancer Center announced a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies; 10x Genomics’ Chromium Single Cell Gene Expression and Xenium In Situ platforms in publication; and more.

    Sep 25, 2024

  • A Pill That Triggers a Desire to Exercise? Maybe... For Now, Just Go to the Gym

    Bio-IT World | What Wegovy has done for people who want to lose weight but dislike the work involved might one day find its match with a pill that pumps up a person’s desire to exercise—all by adjusting their level of interleukin 15 (IL-15), a cytokine that in the brain stimulates locomotor activity. At least that’s one of the promising possibilities dredged up by a study in mice finding a muscle-brain pathway controlling “eagerness to train more when we exercise."

    Sep 24, 2024